🇺🇸 FDA
Patent

US 10428057

Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease

granted A61PA61P25/00A61P25/02

Quick answer

US patent 10428057 (Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease) held by The Board of Regents of the University of Texas System expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
46
CPC classes
A61P, A61P25/00, A61P25/02, A61P25/04, A61P25/14